Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis

Alexandre W. S. de Souza*, Karina de Leeuw, Mirjan M. van Timmeren, Pieter C. Limburg, Coen A. Stegeman, Marc Bijl, Johanna Westra, Cees G. M. Kallenberg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)
413 Downloads (Pure)

Abstract

The objective of this study was to evaluate whether levels of high mobility group box 1 (HMGB1) in granulomatosis with polyangiitis (GPA) patients are associated with carotid atherosclerosis, related to levels of soluble receptor for advanced glycation end-products (sRAGE) and influenced by immunosuppressive or lipid-lowering therapy. Twenty-three GPA patients and 20 controls were evaluated for HMGB1- and sRAGE levels and for carotid atherosclerosis using ultrasound to determine intima-media thickness (IMT). In vitro the effect of atorvastatin on the production of HMGB1 by lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVEC) was assessed. Serum HMGB1 and sRAGE levels did not differ between patients and controls. A negative correlation was found between sRAGE and maximum IMT but HMGB1 and carotid IMT were not related. HMGB1 levels were reduced in GPA patients on statins and prednisolone. In vitro, atorvastatin reduced HMGB1 levels in supernatants of activated HUVEC. In conclusion, carotid IMT is inversely correlated with sRAGE levels but not with HMGB1 levels. Statins and prednisolone are associated with reduced serum HMGB1 levels and atorvastatin decreases HMGB1 release by activated HUVEC in vitro, indicating an additional anti-inflammatory effect of statins.

Original languageEnglish
Article numbere96067
Number of pages6
JournalPLoS ONE
Volume9
Issue number4
DOIs
Publication statusPublished - 28-Apr-2014

Keywords

  • ANCA-ASSOCIATED VASCULITIS
  • HUMAN ENDOTHELIAL-CELLS
  • WEGENERS-GRANULOMATOSIS
  • DISEASE CHARACTERISTICS
  • HMGB1 LEVELS
  • HYPERLIPIDEMIA
  • INFLAMMATION
  • ACTIVATION
  • PROTEIN
  • STRESS

Fingerprint

Dive into the research topics of 'Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis'. Together they form a unique fingerprint.

Cite this